NEW YORK (GenomeWeb) – Following the initial US regulatory approval of Thermo Fisher Scientific's next-generation sequencing-based companion diagnostic panel, the company is hoping to rapidly expand the indications for the test into new drug/biomarker combinations and cancer types.

"This is a long game and the true opportunity for this test will only be realized if Thermo is successful in keeping up with adding additional markers," said Ryan Keeling, chief operating officer at Diaceutics, a company that consults drugmakers in their personalized drug development efforts.  

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.